Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025Hematology

Challenges and opportunities in the long-term management of immune-mediated TTP

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAaron Boothby

Discussion

Loading...

Member takes

Overview

Review identifies long-term sequelae and challenges in monitoring immune-mediated thrombotic thrombocytopenic purpura, suggesting improved strategies.

Key Points

  • Long-term management of immune-mediated thrombotic thrombocytopenic purpura presents significant challenges and emerging opportunities.
  • Notable long-term sequelae of the condition include obesity and chronic kidney disease, among others.
  • Exploration of immune suppression strategies is critical for effective management of immune-mediated thrombotic thrombocytopenic purpura.
  • Highlighting the importance of ongoing monitoring to improve outcomes in patients with TTP.

Cite This Study

Aaron Boothby (2025) studied this question.

synapsesocial.com/papers/6940224e2d562116f28fc16chttps://doi.org/10.1182/hematology.2025000758
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease2024 · 15 citations
  2. 2Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality2021 · 432 citations
  3. 3Thrombotic thrombocytopenic purpura and defective apoptosis due to CASP8/10 mutations: the role of mycophenolate mofetil2019 · 8 citations
  4. 4Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment2022 · 12 citations
  5. 5How I treat thrombotic thrombocytopenic purpura in pregnancy2020 · 87 citations